Alzheimer's Disease Research Center
Alzheimer's Disease Research Center
批准号:
10622633
负责人:
DAVID M. HOLTZMAN
金额:
$307.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-05-15 至 2025-04-30
关键词:
AccelerationAddressAgeAlzheimer disease preventionAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAmyloidAreaAutopsyBasic ScienceBehavioralBiological MarkersBiopsyBloodBrainCerebrospinal FluidClinicalClinical SciencesCognitiveCollaborationsCommunitiesConsentDNADataData SetDementiaDermalDevelopmentDiagnosisDiseaseEnsureEnvironmentEtiologyFacultyFibroblastsFinancial SupportFosteringFunctional Magnetic Resonance ImagingFundingGeneticGoalsGrantImageInternationalKnowledgeMemoryMolecular ProfilingMulticenter StudiesNational Institute on AgingParticipantPathogenesisPathologicPerformancePersonsPlasmaPopulationPositron-Emission TomographyPrevention trialProductivityPsychometricsResearchResearch PersonnelResearch Project GrantsResourcesRestScientistServicesSkinStudentsSymptomsThinkingTissuesTrainingUniversitiesWashingtonWorkbrain magnetic resonance imagingbrain tissuecareer developmentclinical centerclinical phenotypecohortdata managementdesigndisorder preventioneducation researcheffective therapyinduced pluripotent stem cellinnovationinstrumentmetropolitanmild cognitive impairmentmolecular markermultidisciplinarymultimodalityneuropathologynormal agingoutreachpre-clinicalpreventprogramsracial diversityrecruitrepositoryskillsstatisticsstudent trainingtau Proteinstransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Overall Project Summary
The Washington University Charles F. and Joanne Knight Alzheimer Disease Research Center (Knight
ADRC) initiates, fosters, and supports the performance of innovative, cutting-edge research on Alzheimer
disease (AD) and related dementias (ADRD) with regard to the etiology, pathogenesis, diagnosis, treatment,
and prevention of disease. The Knight ADRC's efforts thus fully align with the primary goal of the National
Alzheimer's Project Act of 2011, “to prevent and effectively treat ADRD by 2025”. We provide well-
characterized research participants (persons with symptomatic AD and age-matched controls), their clinical,
psychometric, and imaging data, and their tissue (DNA, CSF, plasma, dermal fibroblasts, iPSCs, brain tissue)
to research projects. We also provide intellectual and financial support to scientists at Washington University,
at other Alzheimer Disease Centers, and the research community nationally and internationally and engage in
formal and informal collaborations, including multi-disciplinary/multi-Center studies and the initiatives
sponsored by the National Institute on Aging, the National Alzheimer Coordinating Center, and the National
Centralize Repository for ADRD. Historically, our Center has focused on the earliest stages of dementia to
identify the initial clinical and pathologic changes that distinguish AD from normal aging. Our approach is
balanced between clinical and basic science domains with emphasis on interdisciplinary efforts. We will
continue our training of students, fellows and junior faculty in clinical and basic science research skills. We will
continue to engage in outreach activities to transfer information on ADRD to lay and professional audiences.
We are committed to assuring that our research cohort reflects the racial diversity of the greater metropolitan
St. Louis area and will continue activities that promote the inclusion of these populations in research.
This renewal application includes seven Cores, plus the new Research Education Component (REC):
A: Administration, B: Clinical, C: Data Management and Statistics, D: Neuropathology, E: Outreach,
Recruitment, and Engagement, F: Biomarker, G: Genetics and High Throughput -Omics.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.jpsychires.2022.10.026
发表时间:
2022-12
期刊:
JOURNAL OF PSYCHIATRIC RESEARCH
影响因子:
4.8
作者:
[Wolfova, Katrin, Wu, Di, Weiss, Jordan, Cermakova, Pavla, Kohler, Hans-Peter, Skirbekk, Vegard Fykse, Stern, Yaakov, Gemmill, Alison, Tom, Sarah E.]
通讯作者:
Tom, Sarah E.
Vascularized Brain Assembloids With Enhanced Cellular Complexity Provide Insights Into the Cellular Deficits of Tauopathy.
细胞复杂性增强的血管化大脑组合体为了解 Tau 蛋白病的细胞缺陷提供了见解。
DOI:
10.1093/stmcls/sxad086
发表时间:
2024
期刊:
Stem cells (Dayton, Ohio)
影响因子:
--
作者:
[Sun,Xiaohuan, Kofman,Simeon, Ogbolu,VictorC, Karch,CelesteM, Ibric,Larisa, Qiang,Liang]
通讯作者:
Qiang,Liang
DOI:
10.3390/ncrna8010009
发表时间:
2022-01-13
期刊:
Non-coding RNA
影响因子:
4.3
作者:
[Zhang J, Eteleeb AM, Rozycki EB, Inkman MJ, Ly A, Scharf RE, Jayachandran K, Krasnick BA, Mazur T, White NM, Fields RC, Maher CA]
通讯作者:
Maher CA
DOI:
10.3389/fnagi.2022.935279
发表时间:
2022
期刊:
Frontiers in aging neuroscience
影响因子:
4.8
作者:
[]
通讯作者:
DOI:
10.1089/heq.2021.0136
发表时间:
2022
期刊:
Health equity
影响因子:
2.7
作者:
[]
通讯作者:
共 7 条
Cerebral amyloid angiopathy: Role of ApoE, innate immunity, and meningeal lymphatics
-
批准号:10674679
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2022
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
-
批准号:10667466
-
项目类别:
-
资助金额:$53.02万
-
财政年份:2021
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
APOE effects on glial lipid metabolism and 25-hydroxycholesterol: Effects on aging and AD-related pathology
-
批准号:10407944
-
项目类别:
-
资助金额:$54.01万
-
财政年份:2021
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administration Core
-
批准号:10622634
-
项目类别:
-
资助金额:$80.27万
-
财政年份:2020
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Sleep and Circadian Rhythms in Alzheimer Disease: Potential bi-directional relationship with tau
-
批准号:9815588
-
项目类别:
-
资助金额:$369.43万
-
财政年份:2019
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Nervous System Development and Injury
-
批准号:9386458
-
项目类别:
-
资助金额:$0.83万
-
财政年份:2016
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:8779836
-
项目类别:
-
资助金额:$59.46万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:9060227
-
项目类别:
-
资助金额:$55.3万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Novel Strategies and Mechanisms to Target APOE and Alzheimer's Disease
-
批准号:9814735
-
项目类别:
-
资助金额:$376.01万
-
财政年份:2014
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administrative Core
-
批准号:10006905
-
项目类别:
-
资助金额:$7.01万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8642679
-
项目类别:
-
资助金额:$112.94万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Dynamic Regulation of Amyloid-^ in the CNS
-
批准号:8331629
-
项目类别:
-
资助金额:$29.84万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8838268
-
项目类别:
-
资助金额:$112.94万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Effects of the Sleep/Wake Cycle on A-Beta, Tau and Spreading
-
批准号:10006907
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Neuronal LRP1 and HSPG in Pathological Spreading of A-Beta and Tau
-
批准号:10246278
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Neuronal LRP1 and HSPG in Pathological Spreading of A-Beta and Tau
-
批准号:10006909
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Administrative Core
-
批准号:10246274
-
项目类别:
-
资助金额:$6.79万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8467068
-
项目类别:
-
资助金额:$110.69万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synaptic, Cellular Modulation of Abeta Metabolism
-
批准号:9764499
-
项目类别:
-
资助金额:$146.62万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
Regional, Synpatic, Cellular Modulation of Abeta Metabolism
-
批准号:8268731
-
项目类别:
-
资助金额:$116.73万
-
财政年份:2012
-
负责人:DAVID M. HOLTZMAN
-
依托单位:
海外基金